ABSTRACT
Objective To observe the efficacy of Danqi Yishen capsule in the treatment of diabetic nephrop-athy(DN),and the effect on laboratory indicators.Methods From March 2016 to December 2016,70 patients with DN in the Traditional Chinese Medicine Hospital of Shanxi Province were selected and divided into control group and observation group according to the different treatment method,with 35 cases in each group.The control group was given basic symptomatic treatment,and the observation group was given Danqi Yishen capsule on the basis of treat-ment in the control group.Both two groups were treated for 8 weeks.The clinical efficacy and changes of laboratory indicators were compared between the two groups.Results The total effective rate of the observation group was significantly higher than that of the control group (88.57% vs.62.86%),and the difference was statistically signifi-cant(P＜0.05).After treatment,the levels of fasting plasma glucose(FPG),2h postprandial blood glucose(2hPG),total cholesterol(TC),triglyceride(TG) and low-density lipoprotein cholesterol(LDL-C) in the observation group were (5.81 ±0.75)mmol/L,(7.64 ±2.12) mmol/L,(4.91 ±1.03) mmol/L,(1.71 ±0.46) mmol/L,(2.25 ± 0.69)mmol/L,respectively,which were significantly lower than those in the control group [(6.37 ±0.92)mmol/L,(8.96 ±1.97)mmol/L,(4.91 ±1.03)mmol/L,(2.17 ±0.52)mmol/L,(3.26 ±1.05)mmol/L](t ＝2.791,2.698,3.321,3.920,4.756,all P＜0.05).The levels of 24h urinary protein excretion(UAER),urinary β2-micro-globulin(β2-MG),urinary albumin and creatinine ratio(ACR) in the observation group were (104.12 ±0.61)mg/24h,(256.72 ±96.43)μg/L,(73.86 ±33.12),respectively,which were significantly lower than those in the control group [(139.87 ±38.45 ) mg/24h,( 431.12 ±97.84 ) μg/L,( 125.84 ±38.96 )] ( all P ＜0.05 ). Conclusion Danqi Yishen capsule can significantly relieve the clinical symptoms in patients with DN,and improve the therapeutic effect.Its mechanism may be associated with lowering blood glucose,regulating blood lipids and reducing urinary protein.
ABSTRACT
Objective To explore the effects of Yishen Capsule on the soluble endothelium protein C receptor (sEPCR) and P-selectin (CD62P) as well as the serum levels of immunoglobulin (Ig) and complement 3 (C3) in patients with chronic glomerulonephritis (CGN). Methods The changes of sEPCR and CD62P levels in plasma as well as Ig and C3 levels in serum were assessed in 40 normal subjects and 78 patients before and after treatment by double-antibody enzyme-linked immunosorbent assay, flow cytometry and immunoturbidimetry, respectively. Results Compared with those in normal group before treatment, the levels of sEPCR and CD62P in plasma as well as IgA in serum increased obviously (P<0.01), and the levels of IgG and IgM as well as C3 in serum decreased significantly in CGN patients (P<0.01). After three months' treatment with Yishen Capsule, the levels of sEPCR and CD62P in plasma and IgA in serum decreased significantly (P<0.05 or P<0.01), and the levels of IgG and IgM in plasma as well as C3 in serum increased obviously (P<0.05 or P<0.01). Conclusion The mechanism of Yishen Capsule's effect in treating patients with CGN may be correlated with decreasing sEPCR and CD62P levels in plasma as well as regulating the levels of Ig in serum and C3.